COMPANY PROFILE

Chase Therapeutics

Explore full profile

Early-stage, product-based specialty pharmaceutical company

Washington DC, United StatesFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Chase Therapeutics

Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company dedicated to developing superior treatments for brain diseases. The company leverages cutting-edge research to identify and inhibit contributory factors that could prove clinically beneficial. Chase Therapeutics operates in the pharmaceutical industry, focusing on neuroscience and neurotherapeutics. Its primary clients include patients suffering from brain diseases and medical professionals seeking advanced treatment options. The company generates revenue through the development and commercialization of its pharmaceutical products. Chase Therapeutics aims to address the unmet medical needs in the treatment of brain diseases, providing innovative solutions that improve patient outcomes.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Washington DC, United States
Employees: 2
Open positions: None listed
Dealroom signal: 54.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Oct 2021	$20M	$80M	Brain Trust Accelerator Fund · Rise of the Rest · Makana Holdings · China Link Asia Holdings	—
EARLY VC✓Equity / VC	Oct 2019	$0	—	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Chase Therapeutics website traffic

Latest recorded traffic for Chase Therapeutics is 70 monthly website visits, down 83.7% over the last three months. Chase Therapeutics's team grew 0% over the past year.

Latest monthly visits70 3-month web change-83.7% 1-year team growth0%

Monthly website visitsJun 2018–Feb 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ENEncefaDevelops biologics that specifically modulate a key age-related target, to fight neurodegenerative, auto-immune, and more broadly age-related diseases	Paris, France	Operational	1	$250K	—
BRBrainStormAutologous Stem Cell Therapeutics	Petah Tikva, Israel	Operational
KEKernelNeuroscience as a Service enables on-demand access to the world's most advanced brain recording technology	Culver City, United States	Operational
NENerviveFor-profit c-corp that is developing the vitalflow, an emergency treatment for stroke and traumatic brain injury	Akron, United States	Operational
XPX4 PharmaceuticalsClinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment	Cambridge, United States	Operational
DADarmiyanDarmiyan has developed a software platform that detects Alzheimer’s disease up to fifteen years before symptoms	San Francisco, United States	Operational
MTMicroVention TerumoCatheter-based neuroendovascular technologies for cerebral aneurysms and other neurovascular diseases	Aliso Viejo, United States	Acquired
NENeuroVasxNeuroVasx is engaged in the development of technologies for the minimally-invasive treatment of hemorrhagic and ischemic strokes	Maple Grove, United States	Operational